Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

Omacetaxine, a protein synthesis inhibitor, is indicated in the United States for the treatment of patients with chronic‐phase (CP) or accelerated‐phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to 2 or more tyrosine kinase inhibitors.

[1]  F. Nicolini,et al.  Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives. , 2014, Leukemia research.

[2]  M. Baccarani,et al.  Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. , 2013, Clinical lymphoma, myeloma & leukemia.

[3]  M. Baccarani,et al.  Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors , 2013, Haematologica.

[4]  I. Flinn,et al.  Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.

[5]  H. Kantarjian,et al.  Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. , 2012, Blood.

[6]  J. Cayuela,et al.  Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib‐resistant chronic myeloid leukaemia patient harbouring the BCR‐ABL1 T315I gatekeeper mutation , 2012, British journal of haematology.

[7]  T. Brümmendorf,et al.  Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. , 2012, Blood.

[8]  H. Kantarjian,et al.  Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. , 2011, Blood.

[9]  T. Holyoake,et al.  Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells , 2011, Leukemia.

[10]  Meir Wetzler,et al.  Omacetaxine as an anticancer therapeutic: what is old is new again. , 2011, Current pharmaceutical design.

[11]  J. Magaud,et al.  The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. , 2010, Clinical lymphoma, myeloma & leukemia.

[12]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[13]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[14]  H. Kantarjian,et al.  Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009 , 2009, Cancer.

[15]  M. Baccarani,et al.  Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. , 2009, Blood.

[16]  S. Lowe,et al.  Altering Chemosensitivity by Modulating Translation Elongation , 2009, PloS one.

[17]  Jorge Cortes,et al.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia. , 2009, Blood.

[18]  Yiguo Hu,et al.  Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-Induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice , 2009, Leukemia.

[19]  H. Kantarjian,et al.  Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. , 2007, Blood.

[20]  C. Preudhomme,et al.  Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation , 2007, Haematologica.

[21]  H. Kantarjian,et al.  New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance , 2006, Annals of Internal Medicine.

[22]  M. Baccarani,et al.  Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia , 2006, Clinical Cancer Research.

[23]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[24]  Susan Branford,et al.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.

[25]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[26]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[27]  G. Karpova,et al.  Selective inhibition of the polypeptide chain elongation in eukaryotic cells. , 1992, Biochimica et biophysica acta.